Kestra Medical Technologies, Ltd. (KMTS) · Sep 14, 2026 · Earnings

Kestra posts 60% revenue growth, raises FY27 guide as losses widen

Beat — Revenue $31.0M vs ~$29.0M consensus

Kestra delivered a revenue beat and lifted FY27 guidance, but heavier spending, debt costs and cash burn keep profitability out of reach.

Kestra is a commercial-stage wearable cardiac-device company scaling its ASSURE wearable cardioverter defibrillator through market expansion, new territories and deeper prescriber adoption. Its prior-quarter story already featured rapid revenue growth, commercial-team expansion and improving margins, so this filing is mainly a test of whether that ramp is translating into durable operating leverage.

The quarter beat the revenue bar and lifted the full-year target. Revenue reached $31.0 million, up 60% year over year, versus a published Q1 consensus of roughly $29.0 million; the company attributed the growth to WCD market expansion, share gains, new territories, payer mix and billing improvements. FY27 revenue guidance also rose to $141 million from $137 million, implying 48% growth over FY26.

MetricQ1 FY27Prior comparison / expectation
Revenue$31.0M$19.4M prior year; ~$29.0M consensus
Gross margin56.5%45.7% prior year
GAAP net loss$(44.1)M$(25.8)M prior year; $(0.75) per share vs ~$0.62 loss consensus
Adjusted EBITDA loss$(24.0)M$(19.4)M prior year
Cash, cash equivalents and investments$244.7M$201.2M prior year
FY27 revenue guidance$141MRaised from $137M

The core economics improved, but the company is still spending faster to chase growth. Gross margin expanded to 56.5% from 45.7%, a meaningful sign that volume, payer mix and cost programs are improving the business model. 〔0〕 But adjusted operating expenses rose to $44.2 million from $30.3 million as Kestra expanded commercially and accelerated R&D, leaving adjusted EBITDA losses wider at $24.0 million versus $19.4 million. 〔1〕

The headline loss overstates the operating deterioration, but cash consumption remains material. GAAP net loss included a $6.3 million debt-extinguishment charge, making the $44.1 million loss look worse than the underlying operating result; nevertheless, operating cash use was still $32.3 million and capital spending was $8.3 million. The balance sheet had $244.7 million of cash and investments, plus approximately $75 million of committed unused term-loan capacity, giving management about $320 million of stated liquidity.

Bottom line: This was a genuine growth beat with a modestly stronger outlook, and the margin trend supports the commercial ramp. The catch is that Kestra has not yet converted growth into lower losses or positive cash flow, so the business story improves more than the profitability story.

What to watch next

Q1 earnings call, September 14

Original filing on SEC EDGAR

Kestra posts 60% revenue growth, raises FY27 guide as losses widen | KMTS Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.